Compare STKE & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKE | LGVN |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 34.0M |
| IPO Year | N/A | 2021 |
| Metric | STKE | LGVN |
|---|---|---|
| Price | $1.60 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 185.8K | ★ 665.9K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $552.94 | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $0.48 |
| 52 Week High | $7.75 | $1.80 |
| Indicator | STKE | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 39.01 |
| Support Level | $1.50 | $0.74 |
| Resistance Level | $1.65 | $0.99 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 89.17 | 2.71 |
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.